Daiwa Securities Group Inc. Decreases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Daiwa Securities Group Inc. cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,534 shares of the medical equipment provider’s stock after selling 4,039 shares during the period. Daiwa Securities Group Inc.’s holdings in Intuitive Surgical were worth $21,096,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Liberty Capital Management Inc. raised its position in shares of Intuitive Surgical by 3.8% during the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 30 shares in the last quarter. Miracle Mile Advisors LLC raised its position in Intuitive Surgical by 2.3% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock valued at $485,000 after purchasing an additional 32 shares during the period. Ausdal Financial Partners Inc. boosted its holdings in shares of Intuitive Surgical by 1.5% in the 4th quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after purchasing an additional 33 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 10.7% in the 4th quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 33 shares during the period. Finally, Modera Wealth Management LLC increased its position in shares of Intuitive Surgical by 2.0% during the 3rd quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock valued at $501,000 after purchasing an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $374.17 on Thursday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company has a market capitalization of $132.62 billion, a price-to-earnings ratio of 74.39, a price-to-earnings-growth ratio of 5.88 and a beta of 1.36. The company’s 50-day simple moving average is $387.56 and its two-hundred day simple moving average is $342.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period last year, the firm earned $0.91 earnings per share. Equities analysts expect that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now directly owns 189 shares of the company’s stock, valued at approximately $69,958.35. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Myriam Curet sold 4,318 shares of the company’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the transaction, the executive vice president now directly owns 189 shares of the company’s stock, valued at $69,958.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,373,093.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $325.00 to $425.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 24th. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Wells Fargo & Company increased their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $375.70.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.